ArticleLeukemia2024
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Open access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
10.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis.Bone marrow transplantation · 2026Pooled it
- HLH-like syndromes associate with increased risk of death and CD19- relapse after CAR T in pediatric B-ALL.Blood advances · 2026Observational
- Review
- Sequence and structural determinants of efficacious de novo chimaeric antigen receptors.Nature biomedical engineering · 2026Article
- Incorporating Immunotherapies into the Evolving Standard of Care for Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.Paediatric drugs · 2026Review
- Differential cytokine architecture in patients treated with CART19 versus CART22.Journal for immunotherapy of cancer · 2026Article
- The evolving landscape of CAR T cell therapy in children and young adults with B cell acute lymphoblastic leukemia.Molecular therapy. Oncology · 2026Review
- CD22 as a Target for Hematological Malignancies and Autoimmune Diseases.International journal of molecular sciences · 2026Review
- Enhancing persistence while managing cytokine release syndrome to embrace next-generation CAR-T cell therapy.Journal of translational medicine · 2026Review
- Chimeric antigen receptor T-cell therapies related to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: Diagnosis, high-risk factors, and management.Chinese medical journal · 2026Review
- Roads and detours for CAR T cell therapy in autoimmune diseases.Nature reviews. Drug discovery · 2026Review
- Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.Molecular therapy. Oncology · 2026Review
- Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia.Blood advances · 2026Article
- A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.Blood · 2026Article
- Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies.Cytotherapy · 2026Article
- Overcoming Resistance and Relapse in CAR-T and CAR-NK Cell Therapies: From Bench to Bedside.Research (Washington, D.C.) · 2026Article
- Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.Journal for immunotherapy of cancer · 2025Article
- Sequence and structural determinants of efficaciousbioRxiv : the preprint server for biology · 2025Article
- Comprehensive omics-based classification system in adult patients with B-cell acute lymphoblastic leukemia.Molecular oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 2 institutions in 1 country.
Liora M Schultz *Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Nikeshan Jeyakumar *Division of Hematology, Stanford University, Stanford, CA, USA.
Anne Marijn KramerCenter for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.ORCID 0000-0001-5239-7343
Bita SahafCenter for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.
Hrishi SrinageshDivision of Hematology, Stanford University, Stanford, CA, USA.
Parveen ShirazDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
Neha AgarwalDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
Mark HamiltonDivision of Hematology, Stanford University, Stanford, CA, USA.
Courtney EricksonDivision of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Ashley JacobsDivision of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Jennifer MoonDivision of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Christina BaggottDivision of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Sally AraiDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
Sushma BharadwajDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
Laura J JohnstonDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
Michaela LiedtkeDivision of Hematology, Stanford University, Stanford, CA, USA.
Robert LowskyDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
Everett MeyerDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
Robert NegrinDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
Andrew RezvaniDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
Judy ShizuruDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.ORCID 0000-0003-3246-4726
Surbhi SidanaDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.ORCID 0000-0003-3288-7614
Emily EgelerCenter for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.
Sharon MavroukakisCenter for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.
Ramya TunuguntlaLaboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.
Nikolaos Gkitsas-LongLaboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.
Aidan RetherfordLaboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.
Annie Kathleen BrownLaboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.
Anne-Louise Gramstrap-PetersenLaboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.
Raquel Martin IbañezLaboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.
Steven A FeldmanCenter for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.
David B MiklosCenter for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.ORCID 0000-0003-0717-4305
Crystal L MackallDivision of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.ORCID 0000-0001-6323-4304
Kara L DavisDivision of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Matthew FrankCenter for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.
Sneha RamakrishnaDivision of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Lori MufflyCenter for Cancer Cell Therapy, Stanford University, Stanford, CA, USA. lmuffly@stanford.edu.ORCID 0000-0002-9887-6136
Stanford University · USStanford Blood Center · US
Funding
Lymphoma Antigen Density and Circulating Tumor DNA Profiling As Determinants of Novel CAR TherapiesK08CA248968 · NCI · STANFORD UNIVERSITY · PI FRANK, MATTHEW J. · 2020 to 2024
$845kNCI NIH HHS K08 CA248968
Abstract
Chimeric antigen receptor (CAR) T cells targeting CD22 (CD22-CAR) provide a therapeutic option for patients with CD22
Indexed as
Immunotherapy, AdoptivePrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2AdolescentAdultChildChild, PreschoolFemaleHumansMaleMiddle AgedT-LymphocytesYoung AdultCD22 protein, humanReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.